There are many factors that may enhance the CAR-T-cell efficacy in the tumor environment including using antiangiogenesis drugs for increased T-cell infiltration, targeting tumor stroma to improve antitumor effect, and depleting Treg as preconditioning, to TGFβ blocking agent to reduce immunosupression and osteolysis [18]. Here, TGFB1 is linked to neoplasm.